Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/13800
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPingaew R.
dc.contributor.authorSaekee A.
dc.contributor.authorMandi P.
dc.contributor.authorNantasenamat C.
dc.contributor.authorPrachayasittikul S.
dc.contributor.authorRuchirawat S.
dc.contributor.authorPrachayasittikul V.
dc.date.accessioned2021-04-05T03:32:26Z-
dc.date.available2021-04-05T03:32:26Z-
dc.date.issued2014
dc.identifier.issn2235234
dc.identifier.other2-s2.0-84905161366
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/13800-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84905161366&doi=10.1016%2fj.ejmech.2014.07.087&partnerID=40&md5=4c490e6ea3dea932430f55e04459096e
dc.description.abstractA new series of chalcone-coumarin derivatives (9-19) linked by the 1,2,3-triazole ring were synthesized through the azide/alkyne dipolar cycloaddition. Hybrid molecules were evaluated for their cytotoxic activity against four cancer cell lines (e.g., HuCCA-1, HepG2, A549 and MOLT-3) and antimalarial activity toward Plasmodium falciparum. Most of the synthesized hybrids, except for analogs 10 and 16, displayed cytotoxicity against MOLT-3 cell line without affecting normal cells. Analogs (10, 11, 16 and 18) exhibited higher inhibitory efficacy than the control drug, etoposide, in HepG2 cells. Significantly, the high cytotoxic potency of the hybrid 11 was shown to be non-toxic to normal cells. Interestingly, the chalcone-coumarin 18 was the most potent antimalarial compound affording IC50 value of 1.60 μM. Molecular docking suggested that the cytotoxicity of reported hybrids could be possibly due to their dual inhibition of α- and β-tubulins at GTP and colchicine binding sites, respectively. Furthermore, falcipain-2 was identified to be a plausible target site of the hybrids given their antimalarial potency. © 2014 Elsevier Masson SAS. All rights reserved.
dc.subject4 ((1 (3 (3 (2,3 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject4 ((1 (3 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject4 ((1 (3 (3 (3,4 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject4 ((1 (4 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject4 ((1 (4 (3 (3,4,5 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yll)methoxy) 2h chromen 2 one
dc.subject7 ((1 (3 (3 (2,3 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject7 ((1 (3 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject7 ((1 (3 (3 (3,4 dimethoxyphenyl)acryloyl)phenyl) 1 h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject7 ((1 (4 (3 (2,3 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject7 ((1 (4 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject7 ((1 (4 (3 (3,4,5 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subjectalpha tubulin
dc.subjectantimalarial agent
dc.subjectantineoplastic agent
dc.subjectbeta tubulin
dc.subjectchalcone derivative
dc.subjectcoumarin derivative
dc.subjectetoposide
dc.subjectfalcipain 2
dc.subjectunclassified drug
dc.subject1,2,3 triazole derivative
dc.subject4 [[1 [3 [3 (2,3 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject4 [[1 [3 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject4 [[1 [3 [3 (3,4 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject4 [[1 [4 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject4 [[1 [4 [3 (3,4,5 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject7 [[1 [3 [3 (2,3 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject7 [[1 [3 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject7 [[1 [3 [3 (3,4 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject7 [[1 [4 [3 (2,3 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject7 [[1 [4 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject7 [[1 [4 [3 (3,4,5 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subjectantimalarial agent
dc.subjectantineoplastic agent
dc.subjectchalcone derivative
dc.subjectcolchicine
dc.subjectcoumarin derivative
dc.subjectdihydroartemisinin
dc.subjectdoxorubicin
dc.subjectellipticine
dc.subjectetoposide
dc.subjectfalcipain 2
dc.subjectn [n (3 carboxyoxirane 2 carbonyl)leucyl]agmatine
dc.subjecttubulin
dc.subjectantimalarial agent
dc.subjectantineoplastic agent
dc.subjectchalcone
dc.subjectcoumarin
dc.subjectcoumarin derivative
dc.subjectcysteine proteinase
dc.subjecttriazole derivative
dc.subjectantimalarial activity
dc.subjectantineoplastic activity
dc.subjectarticle
dc.subjectcancer cell line
dc.subjectcarbon nuclear magnetic resonance
dc.subjectcycloaddition
dc.subjectcytotoxicity
dc.subjectdrug structure
dc.subjectdrug synthesis
dc.subjectHepG2 cell line
dc.subjecthuman
dc.subjecthuman cell
dc.subjectmolecular docking
dc.subjectPlasmodium falciparum
dc.subjectproton nuclear magnetic resonance
dc.subjectA549 cell line
dc.subjectAGMK cell line
dc.subjectanimal cell
dc.subjectantimalarial activity
dc.subjectArticle
dc.subjectcholangiocarcinoma cell line
dc.subjectcontrolled study
dc.subjectcrystal structure
dc.subjectdrug binding site
dc.subjectdrug cytotoxicity
dc.subjectdrug potency
dc.subjectdrug screening
dc.subjectdrug synthesis
dc.subjecthydrogen bond
dc.subjectIC50
dc.subjectleukemia cell line
dc.subjectlymphatic leukemia
dc.subjectmolecular docking
dc.subjectnonhuman
dc.subjectstructure activity relation
dc.subjectVero cell line
dc.subjectchemistry
dc.subjectdrug effects
dc.subjectmetabolism
dc.subjectprotein conformation
dc.subjectsynthesis
dc.subjecttumor cell line
dc.subjectAntimalarials
dc.subjectAntineoplastic Agents
dc.subjectCell Line, Tumor
dc.subjectChalcone
dc.subjectChemistry Techniques, Synthetic
dc.subjectCoumarins
dc.subjectCysteine Endopeptidases
dc.subjectHumans
dc.subjectMolecular Docking Simulation
dc.subjectPlasmodium falciparum
dc.subjectProtein Conformation
dc.subjectTriazoles
dc.subjectTubulin
dc.titleSynthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationEuropean Journal of Medicinal Chemistry. Vol 85, (2014), p.65-76
dc.identifier.doi10.1016/j.ejmech.2014.07.087
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.